Navigation Links
Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
Date:5/6/2008

of clinical outcomes in cancer patients.

Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates through pre-clinical trials. As drugs progress through this early stage of development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care. In the course of this process, this permits the Company to evaluate oncology drugs for companies by using models that integrate prognostic testing with biomarker discovery.

Champions Biotechnology is dedicated to enhancing preclinical development tools, accelerating development and valuation of oncology drugs, and advancing personalized treatment with a goal to improve the lives of cancer patients globally.

This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Biotechnology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Biotechnology's Form 10-KSB for the fiscal year ended April 30, 2007 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Biotechnology's future results, levels of activity, performance or achievements may not meet these expectations. The Comp
'/>"/>

SOURCE Champions Biotechnology
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
2. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
3. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
4. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... for the second quarter ended June 30, 2015. ... both HETLIOZ and Fanapt" said Mihael H. Polymeropoulos M.D., ... and life cycle management of our products set the ...   Financial Highlights , Total net ...
(Date:7/29/2015)... , July 29, 2015 Asterias Biotherapeutics, ... the emerging field of regenerative medicine, today announced that ... on Monday, August 10, 2015 after the close of ... conference call and webcast on Monday, August 10, 2015 ... discuss the results and corporate developments. For ...
(Date:7/29/2015)... July 29, 2015  Depomed, Inc. (NASDAQ: DEPO ... its Board of Directors, after careful consideration and ... legal advisors, has unanimously rejected the purported revised, ... Pharma plc (NASDAQ: HZNP ) ("Horizon") to ... in an all-stock transaction (the "July 21 Proposal"). ...
Breaking Medicine Technology:Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 2Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 3Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 4Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 5Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 6Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 7Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 8Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 9Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 10Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 11Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 12Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 13Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 14Asterias Biotherapeutics to Report Second Quarter Results on August 10, 2015 2Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 2Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 3Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 4Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 5Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 6Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 7Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 8Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 9
... BOZEN, SUD-TIROL, Italy , July 27, 2010 ... assets from, Italy -based MEDarchiver S.r.l. and Biomedical Technology Consulting S.r.l.,merging ... market, and conducting a re-organization of its,Executive Management, expecting to close ... , , ...
... Sysmex America, Inc., a leading medical diagnostic ... to debut its expanded cell image analysis portfolio during ... Conference and Clinical Lab Expo July 25 - ... DM1200 and DM96 systems for the mid-size to larger ...
Cached Medicine Technology:Health Robotics Surpasses 100 Installations Milestone and Acquires Two I.V. Room of the Future Partner Companies 2Health Robotics Surpasses 100 Installations Milestone and Acquires Two I.V. Room of the Future Partner Companies 3Health Robotics Surpasses 100 Installations Milestone and Acquires Two I.V. Room of the Future Partner Companies 4Sysmex America to Launch Complete Cell Image Analysis Portfolio at AACC 2Sysmex America to Launch Complete Cell Image Analysis Portfolio at AACC 3
(Date:7/29/2015)... ... ... According to The Spirits Business on July 16th, a new study ... perpetuating alcohol use disorders. Humans have the same gene, which is called Rsu1. The ... and has given researchers inklings to explore Rsu1 in humans to abate alcohol addiction ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... anticipating testing regulations imposed by the FDA for nicotine laced liquid products. Their ... electronic cigarettes have raised considerably. E-Cigarettes are particularly troublesome to addiction professionals as ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... Michigan, changed its name in July to Kalamazoo Strength & Conditioning. , The ... , and “reflects the evolution of our training center over the past three ...
(Date:7/29/2015)... , ... July 29, 2015 , ... San Fernando ... on Ultherapy. For a limited time only, patients can get the complete treatment process ... for patients who prefer a non-invasive treatment and have loose or sagging skin. ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... For the ... to be featured in the list of the 50 fastest growing companies in Jacksonville. ... around the business community. On July 16th, a team of Vast Bridges staffers were ...
Breaking Medicine News(10 mins):Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 2Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 3Health News:Harbor Village Urges South Florida Residents to Abstain from the Use of E Cigarettes 2Health News:Harbor Village Urges South Florida Residents to Abstain from the Use of E Cigarettes 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 2Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 4Health News:San Fernando Valley Dermatology Office, Castle Dermatology Institute, is Now Offering a Promotional Price on Ultherapy 2Health News:Vast Bridges Continues Its Swift Growth 2
... , , , TAMPA, Fla., ... and Americans are more health-conscious than they,ve ever been before. As ... a good thing, the combination of an aging population and new ... professionals. Healthcare credentials at any level -- from one-year ...
... September 1, 2009Patients with advanced illnesses more than doubled ... health plan made hospice care more readily accessible, according ... Journal of Palliative Medicine , a peer-reviewed publication ... of Palliative Medicine is the official journal of ...
... promise in the treatment of a myriad of diseases, ... However, developing a scalable system for delivering genes to ... Now a team of Northwestern University researchers has introduced ... technology that combines key properties in one approach: enhanced ...
... , CHICAGO, Sept. 1 Today Jack ... new online video series, called " Living Positive By Design : ... education initiative. The Living Positive By Design campaign, supported ... thoughtful conversations about HIV and AIDS, to confront HIV stigma and ...
... AMR Research , the leading research firm focused on ... announce that Hussain Mooraj, vice president and head of healthcare and ... of the 100 most inspiring people in the life sciences industry. ... edition, "One of the most knowledgeable individuals in the healthcare arena, ...
... , CINCINNATI, Sept. 1 ... of physician office-based patient-education programs has announced that SIGVARIS, ... is expanding to the Skin Care Network to broaden ... dermatologist,s office is an ideal place to increase the ...
Cached Medicine News:Health News:Saving Lives Is a Growth Industry 2Health News:Saving Lives Is a Growth Industry 3Health News:Expanded insurance benefits break down barriers to hospice care, according to new study 2Health News:Promise of nanodiamonds for safer gene therapy 2Health News:Promise of nanodiamonds for safer gene therapy 3Health News:Video: 'Project Runway' Designer Launches New Online Video Series to Educate About Living with HIV and AIDS and Help Combat HIV Stigma 2Health News:Video: 'Project Runway' Designer Launches New Online Video Series to Educate About Living with HIV and AIDS and Help Combat HIV Stigma 3Health News:AMR Research Analyst Named One of the Most Inspiring Individuals in Life Sciences by PharmaVOICE 2Health News:AMR Research Analyst Named One of the Most Inspiring Individuals in Life Sciences by PharmaVOICE 3Health News:SIGVARIS USA Extends Educational Efforts in Healthy Advice's Skin Care Network 2Health News:SIGVARIS USA Extends Educational Efforts in Healthy Advice's Skin Care Network 3
Graether Collar Button micro iris retractor....
... Boston simplus multi-action solution is the first ... not only cleans, disinfects and conditions gas ... daily, with cleaning comparable to the leading ... cushioning system provides comfort upon insertion by ...
Fluoroperm 151 lens meets special needs of certain patients who need exceptional oxygen permeability for specific corneal condition or lifestyle requirements....
... a simultaneous vision lens with ... a series of front and ... Gp delivers up to +3.00 ... multi-aspheric center-distance design works in ...
Medicine Products: